Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.

Authors

Giles W. Robinson
Brent A. Orr
Gang Wu
Sridharan Gururangan
Tong Lin
Roger J. Packer, George Washington UniversityFollow
et al.Follow

Document Type

Journal Article

Publication Date

8-20-2015

Journal

Journal of Clinical Oncology

Volume

33

Issue

24

Inclusive Pages

2646-2654

DOI

10.1200/JCO.2014.60.1591

Comments

PMCID: PMC4534527 [Available on 2016-08-20]

APA Citation

Robinson, G. W., Orr, B. A., Wu, G., Gururangan, S., Lin, T., Qaddoumi, I., . . . Gajjar, A. (2015). Vismodegib exerts targeted efficacy against recurrent sonic hedgehog - subgroup medulloblastoma: Results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. Journal of Clinical Oncology, 33(24), 2646-2654. doi:10.1200/JCO.2014.60.1591

Peer Reviewed

1